drugset / Trial / NCT01683292
Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
In this first study of inhaled apomorphine in Parkinson's disease patients, the primary objective is to find the minimum efficacious dose of apomorphine that is useful in rescuing patients during 'off' periods. Safety, tolerability and pharmacokinetics of inhaled apomorphine will be assessed during the study.
Timeline
- Start
- 2006-01
- Primary completion
- 2006-06
- Completion
- 2007-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apomorphine | Unknown | 0.2 mg | Inhaled |
| Subject | Apomorphine | Unknown | 0.5 mg | Inhaled |
| Subject | Apomorphine | Unknown | 0.8 mg | Inhaled |